Alzheimer's disease starts with a sticky protein called amyloid beta that builds up into plaques in the brain, setting off a chain of events that results in brain atrophy and cognitive decline. The new generation of Alzheimer's ...
Apr 3, 2024
0
52
Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.
Mar 8, 2024
0
10
Cerebrospinal fluid (CSF) and other biomarkers differ for individuals with Alzheimer disease and cognitively normal controls, with the estimated times of divergence varying from 18 to six years before diagnosis, according ...
Mar 2, 2024
0
45
Alzheimer's quietly ravages the brain long before symptoms appear and now scientists have new clues about the dominolike sequence of those changes—a potential window to one day intervene.
Feb 22, 2024
0
2
A new research paper titled "GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects" has been published in Aging.
Feb 15, 2024
0
21
UNC School of Medicine researcher Sarah Cohen, Ph.D., and Ian Windham, a former Ph.D. student from the Cohen lab, have made a new discovery about apolipoprotein E (APOE)—the biggest genetic risk factor for late-onset Alzheimer's ...
Feb 9, 2024
0
64
While newly approved drugs for Alzheimer's show some promise for slowing the memory-robbing disease, the current treatments fall far short of being effective at regaining memory. What is needed are more treatment options ...
Feb 1, 2024
0
123
A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.
Jan 31, 2024
0
15
Five cases of Alzheimer's disease are believed to have arisen as a result of medical treatments decades earlier, reports a team of UCL and UCLH researchers.
Jan 29, 2024
0
8
The prevailing theory on the causes of Alzheimer's disease indicates that they are related to the abnormal accumulation of two proteins, amyloid-beta (Aβ) and tau, in neuronal tissues, but there are still many unknowns concerning ...
Jan 17, 2024
0
0
Amyloid beta (Aβ or Abeta) is a peptide of 39–43 amino acids that appear to be the main constituent of amyloid plaques in the brains of Alzheimer's disease patients. Similar plaques appear in some variants of Lewy body dementia and in inclusion body myositis, a muscle disease. Aβ also forms aggregates coating cerebral blood vessels in cerebral amyloid angiopathy. These plaques are composed of a tangle of regularly ordered fibrillar aggregates called amyloid fibers, a protein fold shared by other peptides such as prions associated with protein misfolding diseases. Research on laboratory rats suggest that the two-molecule, soluble form of the peptide is a causative agent in the development of Alzheimer's and that the two-molecule form is the smallest synaptotoxic species of soluble amyloid beta oligomer
This text uses material from Wikipedia, licensed under CC BY-SA
